Dianthus Therapeutics, Inc.

NASDAQ•DNTH

CEO: Mr. Marino Garcia M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2018-06-21

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Contact Information

7 Times Square, 43rd Floor, New York, NY, 10036, United States

929-999-4055

dianthustx.com

Market Cap

$2.82B

P/E (TTM)

17.5

Dividend Yield

52W High

$88.02

52W Low

$13.37

52W Range

87%

Rank58Top 85.6%

2.3

F-Score

Modified Piotroski Analysis

Based on 9-year fundamentals

Weak • 2.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2017-2025

Financial Dashboard

Q4 2025 Data

Revenue

$284.00K+0.00%

4-Quarter Trend

EPS

$2.59+0.00%

4-Quarter Trend

FCF

-$47.12M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Positive Claseprubart Trial Data Phase 2 MaGic trial showed rapid, statistically significant improvements over placebo in gMG patients, announced September 2025.

CIDP Trial Achieves Early GO Achieved target of 20 confirmed responders early in Phase 3 CAPTIVATE trial for CIDP in March 2026.

Significant Capital Raised Raised $288.4M gross proceeds from September 2025 underwritten public offering to fund development activities.

DNTH212 License Agreement Executed Exclusive license for DNTH212 secured October 2025; Phase 1 study initiated in China in December 2025.

Risk Factors

Continued Operating Losses Expected Incurred $162.3M net loss in 2025; expects significant losses to continue requiring substantial future capital infusion.

Product Development Failure Risk Claseprubart and DNTH212 programs are in development and may fail, materially harming business viability.

Reliance on Third-Party Manufacturing Business depends on CDMOs like WuXi Biologics; supply chain disruptions or quality issues pose material risks.

Intense Competition in Markets Faces strong competition from established biopharma entities in gMG, CIDP, and MMN indications, impacting market penetration.

Outlook

Initiate Global gMG Phase 3 Expect to initiate registrational Phase 3 trial for claseprubart in generalized Myasthenia Gravis (gMG) in mid-2026.

Anticipate MMN Trial Results Anticipate initial top-line results from Phase 2 MoMeNtum trial for MMN patients in the second half of 2026.

DNTH212 Phase 1 Results Expected Expect top-line results from DNTH212 Phase 1 healthy volunteers study in the second half of 2026.

Continue Pipeline Exploration Strategy includes exploring claseprubart in broad range of diseases where classical pathway plays significant role.

Peer Comparison

Revenue (TTM)

ANAB

$234.60M

+157.0%

NUVB

$62.90M

+699.0%

NKTR

$55.23M

-43.9%

Gross Margin (Latest Quarter)

ANAB

199.8%

+99.5pp

DNTH

100.0%

+0.0pp

ATAI

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
PRAX	$6.45B	-22.6	-58.7%	0.0%
DNTH	$2.82B	0.0	0.0%	0.3%
WVE	$2.34B	-10.9	-85.0%	2.8%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-37.5%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 11, 2026

EPS:-$1.06

Revenue:$451.18K

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data